Strayer, David R, Carter, William A, Stouch, Bruce C et al. · PloS one · 2012 · DOI
This study tested whether a drug called rintatolimod (a molecule designed to activate immune responses) could help people with severe ME/CFS. Over 230 patients received either the drug or a placebo twice a week for 40 weeks. Patients who received rintatolimod improved their exercise tolerance by about 21%, and they also needed fewer medications to manage their symptoms.
This is one of the few large, well-controlled trials demonstrating objective, measurable improvement in exercise tolerance in severe ME/CFS patients, offering hope for a potential disease-modifying therapy. The reduction in medication dependence also suggests the drug may address underlying pathology rather than merely masking symptoms. For the research community, this suggests immune dysregulation through TLR pathways warrants further investigation as a therapeutic target.
This study does not establish that rintatolimod is effective in mild or moderate ME/CFS, only in severe cases. It does not identify why the TLR-3 agonist works or prove that immune activation is the root cause of ME/CFS—only that stimulating TLR-3 produces measurable benefit. The modest effect size (21–28%) means the drug does not fully reverse the illness, and long-term safety and durability of benefit remain unknown.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
The first block is for the primary paper and is the citation you should use in research work. The atlas-snapshot line only applies if you are specifically referring to this atlas’s reading of the paper on the date shown.
Primary citation
Strayer, David R, Carter, William A, Stouch, Bruce C, Stevens, Staci R, Bateman, Lucinda, Cimoch, Paul J, et al. (2012). A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.. PloS one. https://doi.org/10.1371/journal.pone.0031334
BibTeX
@article{mecfsatlas-strayer-2012-double-blind,
author = {Strayer, David R and Carter, William A and Stouch, Bruce C and Stevens, Staci R and Bateman, Lucinda and Cimoch, Paul J and Lapp, Charles W and Peterson, Daniel L and Chronic Fatigue Syndrome AMP-516 Study Group and Mitchell, William M},
title = {A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.},
journal = {PloS one},
year = {2012},
doi = {10.1371/journal.pone.0031334},
note = {PubMed: 22431963},
url = {https://www.mecfsatlas.com/evidence/strayer-2012-double-blind},
}Atlas snapshot reference
ME/CFS Atlas. Generator v1 / Scanner v1.4 / policy v0.1. Accessed 2026-05-25. https://www.mecfsatlas.com/evidence/strayer-2012-double-blind
Contribute
Private, reviewed by a human. Not a public comment thread.